Lipid complexes with cationic peptides and OAKs; their role in antimicrobial action and in the delivery of antimicrobial agents

Cellular and Molecular Life Sciences

Volumn 68, Issue 13, 2011, Pages 2177-2188

  Epand, Raquel F ^a   Mor, Amram ^b   Epand, Richard M ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antimicrobial peptides; Cochleates; Drug delivery; Multidrug resistance; Synergistic action

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; ANTIMICROBIAL CATIONIC PEPTIDE; CARDIOLIPIN; COCHLEATE DERIVATIVE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DRUG CARRIER; ERYTHROMYCIN; LIPID NANOPARTICLE; LIPOSOME; MACROGOL; NANOPARTICLE; OLIGOACYLLYSINE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TETRAOLEOYLCARDIOLIPIN; UNCLASSIFIED DRUG; VESOSOME;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL MEMBRANE; BILAYER MEMBRANE; COMBINATION CHEMOTHERAPY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DNA INTERACTION; DRUG STRUCTURE; DRUG TRANSPORT; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HOST RESISTANCE; LIPID ANALYSIS; LIPID MEMBRANE; LIPOSOMAL DELIVERY; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; REVIEW; STRUCTURE ACTIVITY RELATION; SURFACE CHARGE;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LIPOSOMES; LYSINE; MEMBRANE LIPIDS;

BACTERIA (MICROORGANISMS); QUERCUS;

EID: 79960964502     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0711-9     Document Type: Review

References (89)

1. Wang G (2010) Antimicrobial peptides: discovery, design and novel therapeutic strategies. 1-230
2. Epand RM, Epand RF (2010) Biophysical analysis of membrane-targeting antimicrobial peptides: membrane properties and the design of peptides specifically targeting Gram-negative bacteria. In: Wang G (ed) Antimicrobial peptides: discovery, design and novel therapeutic strategies, pp 116-127
3. Epand RM and Epand RF (2010) Bacterial membrane lipids in the action of antimicrobial agents. J Peptide Sci 17:298-305
4. Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11-28
5. Chen FY, Lee MT, Huang HW (2002) Sigmoidal concentration dependence of antimicrobial peptide activities: a case study on alamethicin. Biophys J 82:908-914
6. Matsuzaki K (1998) Magainins as paradigm for the mode of action of pore forming polypeptides. Biochim Biophys Acta 1376:391-400
7. Shai Y (2002) Mode of action of membrane active antimicrobial peptides. Biopolymers 66:236-248
8. Yang L, Gordon VD, Mishra A, Som A, Purdy KR, Davis MA, Tew GN, Wong GCL (2007) Synthetic antimicrobial oligomers induce a composition-dependent topological transition in membranes. J Am Chem Soc 129:12141-12147 (Pubitemid 47556850)
9. Epand RF, Sarig H, Mor A, Epand RM (2009) Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl. Biophys J 97:2250-2257
10. Marchand C, Krajewski K, Lee HF, Antony S, Johnson AA, Amin R, Roller P, Kvaratskhelia M, Pommier Y (2006) Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Res 34:5157-5165 (Pubitemid 44742480)
11. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl HG, de Kruijff B (1999) Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286:2361-2364 (Pubitemid 30016902)
12. Almeida PF, Pokorny A (2009) Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry 48:8083-8093
13. Hornung V, Latz E (2010) Intracellular DNA recognition. Nat Rev Immunol 10:123-130
14. Joshi S, Bisht GS, Rawat DS, Kumar A, Kumar R, Maiti S, Pasha S (2010) Interaction studies of novel cell selective antimicrobial peptides with model membranes and E. coli ATCC 11775. Biochim Biophys Acta 1798:1864-1875
15. Shin S, Kim JK, Lee JY, Jung KW, Hwang JS, Lee J, Lee DG, Kim I, Shin SY, Kim Y (2009) Design of potent 9-mer antimicrobial peptide analogs of protaetiamycine and investigation of mechanism of antimicrobial action. J Pept Sci 15:559-568
16. Matsuzaki K (2009) Control of cell selectivity of antimicrobial peptides. Biochim Biophys Acta 1788:1687-1692
17. Epand RM, Epand RF, Arnusch CJ, Papahadjopoulos-Sternberg B, Wang G, Shai Y (2010) Lipid clustering by three homologous arginine-rich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure. Biochim Biophys Acta-Biomembranes 1798:1272-1280
18. Epand RF, Maloy L, Ramamoorthy A, Epand RM (2010) Amphipathic helical cationic antimicrobial peptides promote rapid formation of crystalline states in the presence of phosphatidylglycerol: lipid clustering in anionic membranes. Biophys J 98:2564-2573
19. Epand RM, Rotem S, Mor A, Berno B, Epand RF (2008) Bacterial membranes as predictors of antimicrobial potency. J Am Chem Soc 130:14346-14352
20. Epand RF, Sarig H, Ohana D, Papahadjopoulos-Sternberg B, Mor A, Epand RM (2011) Physical properties affecting cochleate formation and morphology using antimicrobial oligo-acyl-lysyl peptide mimetics and mixtures mimicking the composition of bacterial membranes in the absence of divalent cations. J Phys Chem B 115:2287-2293
21. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KP, van Strijp JA (2001) Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 193:1067-1076 (Pubitemid 32436200)
22. Camargo IL, Neoh HM, Cui L, Hiramatsu K (2008) Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycinintermediate phenotype. Antimicrob Agents Chemother 52:4289-4299
23. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS (2009) Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:2312-2318
24. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A (2009) The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5:e1000660
25. Lehrer RI, Barton A, Ganz T (1988) Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. J Immunol Methods 108:153-158
26. Gould D (2009) Effective strategies for prevention and control of Gram-negative infections. Nurs Stand 23:42-46
27. Maragakis LL (2010) Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit Care Med 38:S345-S351
28. Singh S (2010) Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol 10:7906-7918
29. Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS (2005) Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol 391:40-57 (Pubitemid 40254028)
30. Parr MJ, Ansell SM, Choi LS, Cullis PR (1994) Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta 1195:21-30 (Pubitemid 24318087)
31. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199
32. Paliwal SR, Paliwal R, Mishra N, Mehta A, Vyas SP (2010) A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. Curr Cancer Drug Targets 10:343-353
33. Parr MJ, Masin D, Cullis PR, Bally MB (1997) Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280:1319-1327 (Pubitemid 27166729)
34. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2006) The blood-brain barrier and brain drug delivery. J Nanosci Nanotechnol 6:2712-2735 (Pubitemid 44579941)
35. 2+ and protein on the thermotropic behaviour of the negatively charged phospholipid, phosphatidylglycerol. Biochim Biophys Acta 339:432-437
36. Tocanne JF, Ververgaert PH, Verkleij AJ, van Deenen LL (1974) A monolayer and freeze-etching study of charged phospholipids. I. Effects of ions and pH on the ionic properties of phosphatidylglycerol and lysylphosphatidylglycerol. Chem Phys Lipids 12:201-219
37. 2+ on the thermotropic behaviour of phosphatidylglycerol. Chem Phys Lipids 14:97-101
38. Papahadjopoulos D, Poste G, Schaeffer BE, Vail WJ (1974) Membrane fusion and molecular segregation in phospholipid vesicles. Biochim Biophys Acta 352:10-28
39. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G (1975) Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 394:483-491
40. Evans CC, Zasadzinski J (2003) Encapsulating vesicles and colloids from cochleate cylinders. Langmuir 19:3109-3113
41. Walker SA, Kennedy MT, Zasadzinski JA (1997) Encapsulation of bilayer vesicles by self-assembly. Nature 387:61-64 (Pubitemid 27202647)
42. Boyer C, Zasadzinski JA (2007) Multiple lipid compartments slow vesicle contents release in lipases and serum. ACS Nano 1:176-182
43. Zarif L (2002) Elongated supramolecular assemblies in drug delivery. J Control Release 81:7-23
44. Rao R, Squillante E III, Kim KH (2007) Lipid-based cochleates: a promising formulation platform for oral and parenteral delivery of therapeutic agents. Crit Rev Ther Drug Carrier Syst 24:41-61 (Pubitemid 46653059)
45. Livne L, Epand RF, Papahadjopoulos-Sternberg B, Epand RM, Mor A (2010) OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria. FASEB J 24:5092-5101
46. Flach CR, Mendelsohn R (1993) A new infrared spectroscopic marker for cochleate phases in phosphatidylserine-containing model membranes. Biophys J 64:1113-1121 (Pubitemid 23143276)
47. Sternberg B (1996) Liposomes as a model for membrane structure and structural transformations: a liposome album. In: Lasic DD, Barenholz Y (eds) Handbook of nonmedical applications of liposomes, vol IV. From gene delivery and diagnosis to ecology. CRC Press, Boca Raton, pp .271-297
48. Sternberg B (1998) Ultrastructural morphology of cationic liposome-DNA complexes for gene therapy. 395-427
49. Papahadjopoulos-Sternberg B (2005) Comparison of freeze-fracture-with cryo-electron microscopy on molecular assemblies suitable for drug and gene delivery. Microsc Microanal 11:1048-1049
50. Day EP, Ho JT, Kunze RK Jr, Sun ST (1977) Dynamic light scattering study of calcium-induced fusion in phospholipid vesicles. Biochim Biophys Acta 470:503-508 (Pubitemid 8211236)
51. Syed UM, Woo AF, Plakogiannis F, Jin T, Zhu H (2008) Cochleates bridged by drug molecules. Int J Pharm 363:118-125
52. Ramani K, Balasubramanian SV (2003) Fluorescence properties of Laurdan in cochleate phases. Biochim Biophys Acta 1618:67-78 (Pubitemid 37487841)
53. Mannino RJ, Canki M, Feketeova E, Scolpino AJ, Wang Z, Zhang F, Kheiri MT, Gould-Fogerite S (1998) Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Deliv Rev 32:273-287 (Pubitemid 28267413)
54. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ (2000) Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 44:1463-1469 (Pubitemid 30340780)
55. Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, Perlin DS (2000) Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 44:2356-2360 (Pubitemid 30650879)
56. Perez O, Bracho G, Lastre M, Mora N, Del CJ, Gil D, Zayas C, Acevedo R, Gonzalez D, Lopez JA, Taboada C, Turtle C, Solis RL (2004) Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol 82:603-610 (Pubitemid 39563961)
57. Campo JD, Zayas C, Romeu B, Acevedo R, Gonzalez E, Bracho G, Cuello M, Cabrera O, Balboa J, Lastre M (2009) Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods 49:301-308
58. Perez O, Bracho G, Lastre M, Zayas C, Gonzalez D, Gil D, del CJ, Acevedo R, Taboada C, Rodriguez T, Fajardo ME, Sierra G, Campa C, Mora N, Barbera R, Solis RL (2006) Proteliposome-derived cochleate as an immunomodulator for nasal vaccine. Vaccine 24(Suppl 2):S2-S3
59. Gil D, Bracho G, Zayas C, del Campo J, Acevedo R, Toledo A, Lastre M, Perez O (2006) Strategy for determination of an efficient cochleate particle size. Vaccine 24:S92-S93
60. del Campo J, Lindqvist M, Cuello M, Backstrom M, Cabrerra O, Persson J, Perez O, Harandi AM (2010) Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 28:1193-1200
61. Acevedo R, Callico A, del CJ, Gonzalez E, Cedre B, Gonzalez L, Romeu B, Zayas C, Lastre M, Fernandez S, Oliva R, Garcia L, Perez JL, Perez O (2009) Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 49:309-315
62. Gibson B, Duffy AM, Gould FS, Krause-Elsmore S, Lu R, Shang G, Chen ZW, Mannino RJ, Bouchier-Hayes DJ, Harmey JH (2004) A novel gene delivery system for mammalian cells. Anticancer Res 24:483-488 (Pubitemid 38623123)
63. Miclea RD, Varma PR, Peng A, Balu-Iyer SV (2007) Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta 1768:2890-2898 (Pubitemid 350060879)
64. Kates M, Syz JY, Gosser D, Haines TH (1993) pH-dissociation characteristics of cardiolipin and its 2-deoxy analogue. Lipids 28:877-882 (Pubitemid 23297115)
65. Garidel P, Richter W, Rapp G, Blume A (2001) Structural and morphological investigations of the formation of quasi-crystalline phases of 1, 2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG). Phys Chem Chem Phys 3:1504-1513 (Pubitemid 32511015)
66. Matsumoto K, Kusaka J, Nishibori A, Hara H (2006) Lipid domains in bacterial membranes. Mol Microbiol 61:1110-1117 (Pubitemid 44215416)
67. Elder M, Hitchcock P, Mason FRS, Shipley GG (1977) A refinement analysis of the crystallography of the phospholipid, 1, 2-Dilauroyl-DL- phosphatidylethanolamine, and some remarks on lipid-lipid and lipid-protein interactions. Proc Royal Soc London A 354:157-170
68. Hauser H, Pascher I, Pearson RH, Sundell S (1981) Preferred conformation and molecular packing of phosphatidylethanolamine and phosphatidylcholine. Biochim Biophys Acta 650:21-51
69. Boggs JM (1987) Lipid intermolecular hydrogen bonding: influence on structural organization and membrane function. Biochim Biophys Acta 906:353-404
70. Pascher I, Sundell S, Harlos K, Eibl H (1987) Conformation and packing properties of membrane lipids: the crystal structure of sodium dimyristoylphosphatidylglycerol. Biochim Biophys Acta 896:77-88
71. Jacobson K, Papahadjopoulos D (1975) Phase transitions and phase separations in phospholipid membranes induced by changes in temperature, pH, and concentration of bivalent cations. Biochemistry 14:152-161
72. Li XZ, Nikaido H (2009) Efflux-mediated drug resistance in bacteria: an update. Drugs 69:1555-1623
73. Nikaido H (2009) Multidrug resistance in bacteria. Annu Rev Biochem 78:119-146
74. Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56:20-51
75. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749-757
76. Paulsen IT, Brown MH, Skurray RA (1996) Proton-dependent multidrug efflux systems. Microbiol Rev 60:575-608 (Pubitemid 26415669)
77. Paulsen IT, Brown MH, Littlejohn TG, Mitchell BA, Skurray RA (1996) Multidrug resistance proteins QacA and QacB from Staphylococcus aureus: membrane topology and identification of residues involved in substrate specificity. Proc Natl Acad Sci USA 93:3630-3635 (Pubitemid 26127591)
78. DeMarco CE, Cushing LA, Frempong-Manso E, Seo SM, Jaravaza TA, Kaatz GW (2007) Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 51:3235-3239 (Pubitemid 350067534)
79. Paulsen IT, Skurray RA, Tam R, Saier MH Jr, Turner RJ, Weiner JH, Goldberg EB, Grinius LL (1996) The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mol Microbiol 19:1167-1175 (Pubitemid 26111492)
80. Schuldiner S, Granot D, Mordoch SS, Ninio S, Rotem D, Soskin M, Tate CG, Yerushalmi H (2001) Small is mighty: EmrE, a multidrug transporter as an experimental paradigm. News Physiol Sci 16:130-134 (Pubitemid 33570302)
81. Nikaido H (1996) Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 178:5853-5859
82. Su CC, Long F, Yu EW (2011) The Cus efflux system removes toxic ions via a methionine shuttle. Protein Sci 20:6-18
83. Miyamae S, Ueda O, Yoshimura F, Hwang J, Tanaka Y, Nikaido H (2001) A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 45:3341-3346 (Pubitemid 33107844)
84. Morita Y, Kataoka A, Shiota S, Mizushima T, Tsuchiya T (2000) NorM of vibrio parahaemolyticus is an Na(+)-driven multidrug efflux pump. J Bacteriol 182:6694-6697 (Pubitemid 32249252)
85. Davidson AL, Dassa E, Orelle C, Chen J (2008) Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev 72:317-364 (Pubitemid 351822295)
86. Kristiansen JE, Thomsen VF, Martins A, Viveiros M, Amaral L (2010) Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo 24:751-754
87. Pages JM, ibert-Franco S, Mahamoud A, Bolla JM, vin-Regli A, Chevalier J, Garnotel E (2010) Efflux pumps of Gram-negative bacteria, a new target for new molecules. Curr Top Med Chem 10(18):1848-1857
88. Zechini B, Versace I (2009) Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Antiinfect Drug Discov 4:37-50
89. Anantharaman A, Rizvi MS, Sahal D (2010) Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob Agents Chemother 54:1693-1699